<DOC>
	<DOC>NCT01738503</DOC>
	<brief_summary>This is an open-label study in treatment seeking opioid-dependent subjects for safety, tolerability, pharmacokinetics (PK), efficacy markers, and opioid receptor availability of subcutaneous injections of depot buprenorphine after induction and stabilization of treatment seeking subjects onto Subutex.</brief_summary>
	<brief_title>Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Male and female subjects Agree not to take any buprenorphine products other than those administered for the current study throughout participation in the study Body mass index (BMI) of &gt;18.0 to &lt; 33.0 kg/m Participants with a current diagnosis requiring chronic opioid treatment Participants with a history of risk factors of Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or an ECG demonstrating a Fridericia's corrected QT interval (QTcF) &gt;450 msec in males and QTcF &gt; 470 in females at screening Abuse of buprenorphine or use of buprenorphine within 14 days of informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Opioid Dependence, Buprenorphine, Depot, SUBUTEX, RBP-6000</keyword>
</DOC>